Clinical Pharmacokinetics

, Volume 54, Issue 12, pp 1287–1288 | Cite as

Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design

  • Joseph F. Standing
  • Brian J. Anderson
  • Nicholas H.G. Holford
  • Irja Lutsar
  • Tuuli Metsvaht
Letter to the Editor
First Online:

Keywords

Routine Blood Test Opportunistic Sample Optimal Sampling Time Opportunistic Data Routine Blood Sample 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

No funding was received in the preparation of this manuscript. JS, BA, NH, IL, and MT have no conflicts of interest to declare.

References

  1. 1.
    Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52:1601–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Leroux S, Turner MA, Barin-Le Guellec C, Hill H, van den Anker JN, Kearns GL, On behalf of the TINN and GRiP Consortia, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015. doi: 10.1007/s40262-015-0291-1.PubMedGoogle Scholar
  3. 3.
    Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, On behalf of the TINN consortium, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than 3 months of age. Antimicrob Agents Chemother. 2014;58(11):6572–80.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Rees VE, Bulitta JB, Nation RL, Tsuji BT, Sörgel F, Landersdorfer CB. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa. J Antimicrob Chemother. 2015;70(3):818–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Mentre F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn. 2001;28(3):299–319.CrossRefPubMedGoogle Scholar
  6. 6.
    Lutsar I, Trafojer UM, Heath PT, Metsvaht T, Standing J, Esposito S, On behalf of the NeoMero Consortium, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials. 2011;12:215.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Joseph F. Standing
    • 1
  • Brian J. Anderson
    • 2
  • Nicholas H.G. Holford
    • 3
  • Irja Lutsar
    • 4
  • Tuuli Metsvaht
    • 5
  1. 1.Institute of Child HealthUniversity College LondonLondonUK
  2. 2.Department of AnaesthesiologyUniversity of AucklandAucklandNew Zealand
  3. 3.Department of Pharmacology and Clinical PharmacologyUniversity of AucklandAucklandNew Zealand
  4. 4.Department of MicrobiologyUniversity of TartuTartuEstonia
  5. 5.Tartu University ClinicTartuEstonia

Personalised recommendations